Enlonstobart clinical trials
Also written SG001.
How each study uses enlonstobart is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the enlonstobart studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2026 (6)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 3 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 5 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 4
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (6) · CSPC Megalith Biopharmaceutical Co.,Ltd. (5) · Shanghai JMT-Bio Inc. (3) · Fudan University (1) · Hebei Medical University Fourth Hospital (1) · Sun Yat-Sen University Cancer Center (1) · Chongqing University Cancer Hospital (1) · Shanghai Runshi Pharmaceutical Technology Co., Ltd (1)
Often tested with
Tested in the same studies.
Anti-EGFR Antibody-drug Conjugate CPO301 (4) · Bevacizumab (2) · Anbenitamab (2) · Modified FOLFOX6 Regimen (1) · Suvemcitug (1) · Irinotecan (1) · Fluorouracil (1) · Irinotecan sucrosofate (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4, 1 in phase 3
Studies that test enlonstobart, phase 3 first.
- Sep 2027SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC(SYNSTAR 04)Phase 3 · CSPC Megalith Biopharmaceutical Co.,Ltd.
- Dec 2026Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)Phase 1/2 · Sun Yat-Sen University Cancer Center
- Jan 2027A Study of Simmitinib Plus SG001 in Advanced Solid TumorsPhase 1/2 · Shanghai Runshi Pharmaceutical Technology Co., Ltd
- Apr 2027A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.Phase 1/2 · CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Studies
Open first, then newest update. How each study uses enlonstobart is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 19
- A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)RecruitingPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07672223Written as Enlonstobart
- A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or Without SYS6010 as Adjuvant Therapy, in Participants With Pathologically Residual Esophageal Squamous Cell Carcinoma Following Complete Surgical ResectionNot yet recruitingPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07924111Written as SG001
- Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal CancerNot yet recruitingPhase 2Fudan UniversityNCT07810114Written as Enlonstobart
- A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian CancerRecruitingPhase 2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07714668Written as SYS6041, enlonstobart, bevacizumab
- SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC(SYNSTAR 04)Not yet recruitingPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07633873Written as Enlonstobart injection
- A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal CancerNot yet recruitingPhase 2/3Hebei Medical University Fourth HospitalNCT07585279Written as Liposomal irinotecan + 5-FU/LV + bevacizumab + Enlonstobart
- A Study of KN026-based Combination Therapy in HER2-positive Gastric CancerNot yet recruitingPhase 2/3Shanghai JMT-Bio Inc.NCT07332533Written as Enlonstobart
- Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)Not yet recruitingPhase 1/2Sun Yat-Sen University Cancer CenterNCT07288814Written as Mitoxantrone Hydrochloride Liposome & Enlonstobart
- A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.Not yet recruitingPhase 2/3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07251062Written as SYS6010+SG001
- JSKN003 Combined Treatment of HER2-positive Gastric CancerNot yet recruitingPhase 2Shanghai JMT-Bio Inc.NCT06998771Written as Enlonstobart
- A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical CancerNot yet recruitingPhase 2Chongqing University Cancer HospitalNCT06981858Written as Enlonstobart Injection
- A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.Not yet recruitingPhase 1/2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06136988Written as SG001
- A Study of Simmitinib Plus SG001 in Advanced Solid TumorsNot yet recruitingPhase 1/2Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06132217Written as SG001
- A Study of JMT101 in Patients With Metastatic Colorectal CancerNot yet recruitingPhase 2Shanghai JMT-Bio Inc.NCT06089330Written as SG001
- Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)Not yet recruitingPhase 3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05715840Written as SG001 injection
- Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical CancerStatus unknownPhase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04886700Written as SG001
- A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)Status unknownPhase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05068141Written as SG001
- Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOCStatus unknownPhase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04983550Written as SG001
- Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced TumoursStatus unknownPhase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT03852823Written as SG001
Given beside what is tested · 9 — enlonstobart is usual care or a partner of the new treatment
- SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell CarcinomaRecruitingPhase 2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07254585Written as Enlonstobart injection
- SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung CancerNot yet recruitingPhase 2/3Shanghai Chest HospitalNCT07662811Written as Enlonstobart
- SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid TumorsNot yet recruitingPhase 1/2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07622225Written as Enlonstobart
- Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver CancerNot yet recruitingPhase 1/2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT07282509Written as Enlonstobart Injection
- Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)RecruitingPhase 2Fudan UniversityNCT07183865Written as SG001
- SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCCNot yet recruitingPhase 2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT06989671Written as SG001
- Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.Not yet recruitingPhase 1/2Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06682611Written as SG001
- A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid TumorsNot yet recruitingPhase 1/2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05508659Written as SG001
- Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract CancerTerminatedPhase 2CSPC Ouyi Pharmaceutical Co., Ltd.NCT05009953Written as SG001
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
Newly registered1
Codes
What other systems call enlonstobart · ClinicalTrials.gg INT016745
- UNII (FDA) H533QU433MENLONSTOBARTOne source FDA
- NCI Thesaurus C182009EnlonstobartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | H533QU433M | ENLONSTOBART | One source FDA |
| NCI Thesaurus | C182009 | Enlonstobart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.